Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy.

PloS one - 1 Jan 2013

Yu Shaorong, Xiao Xia, Lu Jianwei, Qian Xiaoping, Liu Baorui, Feng Jifeng

Abstract excerpt

Epidermal growth factor receptor monoclonal antibody was approved for treatment of metastatic colorectal cancer patients carrying KRAS wild type DNA. However, recent studies showed that patients with KRAS G13D mutation may benefit from EGFR antibody therapy. In this study we tried to explore whet...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Antibodies, Monoclonal, Humanized
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Cetuximab

Share to Colorectal Neoplasms

Share to ErbB Receptors

Share to ras Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 23874486
DOI: 10.1371/journal.pone.0068022
PMCID: PMC3706612

Genes

KRAS
EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23874486-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy.PMID 23874486Read ↗

Japanese Society of Medical Oncology Clinical Guidelines: RAS (KRAS/NRAS) mutation testing in colorectal cancer patients.Semantic proximity Read ↗

Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.Semantic proximity Read ↗

High sensitive mutation analysis on KRAS gene using LNA/DNA chimeras as PCR amplification blockers of wild-type alleles.Semantic proximity Read ↗

KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.Semantic proximity Read ↗

[KRAS mutation test].Semantic proximity Read ↗

Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.Semantic proximity Read ↗

Modified PNA-PCR method: a convenient and accurate method to screen plasma KRAS mutations of cancer patients.Semantic proximity Read ↗

PCR-based assays versus direct sequencing for evaluating the effect of KRAS status on anti-EGFR treatment response in colorectal cancer patients: a systematic review and meta-analysis.Semantic proximity Read ↗

Reliability of digital PCR in detecting KRAS mutation in colorectal cancer using plasma sample: A systematic review and meta-analysis.Semantic proximity Read ↗

RAS Mutational Status Detection in Tissue, Plasma, and Stool Samples for Colorectal Cancer.Semantic proximity Read ↗

Clinical benefit of high-sensitivity KRAS mutation testing in metastatic colorectal cancer treated with anti-EGFR antibody therapy.Semantic proximity Read ↗

Decreasing relapse in colorectal cancer patients treated with cetuximab by using the activating KRAS detection chip.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.